These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 7639011)
1. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody. Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491 [TBL] [Abstract][Full Text] [Related]
3. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Scheckelhoff MR; Telford SR; Hu LT Vaccine; 2006 Mar; 24(11):1949-57. PubMed ID: 16300863 [TBL] [Abstract][Full Text] [Related]
4. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. de Silva AM; Telford SR; Brunet LR; Barthold SW; Fikrig E J Exp Med; 1996 Jan; 183(1):271-5. PubMed ID: 8551231 [TBL] [Abstract][Full Text] [Related]
5. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292 [TBL] [Abstract][Full Text] [Related]
6. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites. Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; Pêtre J Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340 [TBL] [Abstract][Full Text] [Related]
7. A new approach to a Lyme disease vaccine. Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174 [TBL] [Abstract][Full Text] [Related]
8. Resistance to tick-borne spirochete challenge induced by Borrelia burgdorferi strains that differ in expression of outer surface proteins. Kurtti TJ; Munderloh UG; Hughes CA; Engstrom SM; Johnson RC Infect Immun; 1996 Oct; 64(10):4148-53. PubMed ID: 8926082 [TBL] [Abstract][Full Text] [Related]
9. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Fikrig E; Telford SR; Barthold SW; Kantor FS; Spielman A; Flavell RA Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5418-21. PubMed ID: 1608951 [TBL] [Abstract][Full Text] [Related]
10. Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi. Luke CJ; Huebner RC; Kasmiersky V; Barbour AG Vaccine; 1997; 15(6-7):739-46. PubMed ID: 9178476 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697 [TBL] [Abstract][Full Text] [Related]
12. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Chang YF; Appel MJ; Jacobson RH; Shin SJ; Harpending P; Straubinger R; Patrican LA; Mohammed H; Summers BA Infect Immun; 1995 Sep; 63(9):3543-9. PubMed ID: 7642289 [TBL] [Abstract][Full Text] [Related]
13. Vaccination of natural reservoir hosts with recombinant lipidated OspA induces a transmission-blocking immunity against Lyme disease spirochaetes associated with high levels of LA-2 equivalent antibodies. Kurtenbach K; Dizij A; Voet P; Hauser P; Simon MM Vaccine; 1997 Oct; 15(15):1670-4. PubMed ID: 9364698 [TBL] [Abstract][Full Text] [Related]
14. OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks. Tsao J; Barbour AG; Luke CJ; Fikrig E; Fish D Vector Borne Zoonotic Dis; 2001; 1(1):65-74. PubMed ID: 12653137 [TBL] [Abstract][Full Text] [Related]
15. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. Luke CJ; Carner K; Liang X; Barbour AG J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201 [TBL] [Abstract][Full Text] [Related]
16. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. de Silva AM; Zeidner NS; Zhang Y; Dolan MC; Piesman J; Fikrig E Infect Immun; 1999 Jan; 67(1):30-5. PubMed ID: 9864192 [TBL] [Abstract][Full Text] [Related]
17. Tick transmission of Borrelia burgdorferi to inbred strains of mice induces an antibody response to P39 but not to outer surface protein A. Golde WT; Kappel KJ; Dequesne G; Feron C; Plainchamp D; Capiau C; Lobet Y Infect Immun; 1994 Jun; 62(6):2625-7. PubMed ID: 8188388 [TBL] [Abstract][Full Text] [Related]
18. Abilities of OspA proteins from different seroprotective groups of Borrelia burgdorferi to protect hamsters from infection. Lovrich SD; Callister SM; DuChateau BK; Lim LC; Winfrey J; Day SP; Schell RF Infect Immun; 1995 Jun; 63(6):2113-9. PubMed ID: 7768589 [TBL] [Abstract][Full Text] [Related]